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Abstract: 249 words 32 
Purpose: Anticholinergic burden (ACB) – cumulative effect of anticholinergic medications – is 33 
associated with adverse outcomes in older people but less studied in ‘middle-aged’ populations. 34 
Numerous scales exist to quantify ACB. Aims: to quantify ACB in a large cohort using ten most 35 
common anticholinergic scales;  to assess association of each scale with adverse outcomes; to  36 
assess  overlap in populations identified by each scale. 37 
Methods: Longitudinal analysis of UK Biobank community cohort (502,538 participants, baseline age 38 
37-73, median 6 years follow-up). ACB calculated at baseline using ten scales. Linkage to national 39 
mortality register and hospital episode statistics. Primary outcome: composite of all cause-mortality 40 
or major adverse cardiovascular event (MACE). Secondary outcomes: all-cause mortality, MACE, 41 
fall/fracture, hospital admission with dementia/delirium. Cox Proportional hazard models (hazard 42 
ratios (HR), 95% confidence intervals (CI)) quantified association between ACB scales and outcomes 43 
adjusted for age, sex, socioeconomic status, BMI, smoking, alcohol, physical activity and morbidity 44 
count. 45 
Results: Anticholinergic medication use varied from 8.0%-17.6% depending on scale used. Primary 46 
outcome: ACB significantly associated with all-cause mortality/MACE using each scale.  47 
‘Anticholinergic Drug Scale’ most strongly associated (HR 1.12 [CI 1.11-1.14] per one-point increase 48 
in score) with mortality/MACE. ACB significantly associated with all secondary outcomes. 49 
‘Anticholinergic Effect on Cognition’ scale most strongly associated with dementia/delirium (HR 1.45 50 
[CI 1.30-1.61] per one-point increase). 51 
Conclusions: ACB is associated with adverse outcomes in a middle-older aged population. 52 
Populations identified and effect size differs between scales. Scale choice influences the population 53 
identified as potentially requiring reduction in ACB in clinical practice or intervention trials. 54 
  55 
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CrAS Clinician-rated anticholinergic scale (Han 2008) 
BMI Body Mass Index 
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Introduction 61 
Many frequently prescribed medications, for a range of medical conditions, have anticholinergic 62 
properties.1  The use of multiple anticholinergic medications leads to a cumulative effect, referred to 63 
as anticholinergic burden (ACB). ACB is associated with adverse outcomes in older people, including 64 
mortality, cardiovascular events, falls, and cognitive impairment.2  Several scales exist to quantify 65 
anticholinergic burden,3-12 however there is no consensus regarding the optimal scale.13 It is 66 
recognized that the population identified as being at risk of adverse outcomes may vary depending 67 
on the choice of scale.14-17 These scales differ in the medications they include and the ‘score’ they 68 
assign to specific medications. Scales for measuring ACB tend to classify medications into four 69 
categories from no anticholinergic activity (score = 0) to high anticholinergic activity (score = 3). The 70 
scores are calculated by scoring each individual medication a person is taking and then summing 71 
these to give an overall score. Validations of these scales vary in study design, age of participants, 72 
setting, length of follow-up and methodological quality.13  73 
Studies quantifying the impact of ACB have typically focused on patients aged at least 65 years, and 74 
often much older. It is not clear if findings from ‘high risk’ populations, such as nursing home 75 
residents, are relevant to the larger population of younger, less frail individuals. People aged <65 76 
years can be affected by multiple chronic conditions (multimorbidity), multiple medications 77 
(polypharmacy), and frailty.18 Understanding how ACB impacts such people is vital if the risks 78 
associated with ACB are to be mitigated at a population level. 79 
 80 
Using data from UK Biobank, a large community-based cohort of 502,538 participants aged 37-73, 81 
this study aimed to quantify anticholinergic burden of participants using the ten most frequently 82 
validated anticholinergic scales; assess association of each scale with adverse outcomes previously 83 
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linked to ACB; and assess agreement and degree of overlap in the scales for identifying ACB in the 84 
same population.  85 
 86 
Methods 87 
Study design and participants 88 
UK Biobank is a community-based cohort study of 502,538 participants, recruited between 2006 and 89 
2010 in England, Scotland and Wales. Participants completed a touchscreen questionnaire, interview 90 
with a study nurse, and had physical measurements (e.g. height, weight). All participants gave 91 
informed consent for data collection, analysis and linkage. This study is part of UK Biobank project 92 
14151 with ethical approval from NHS National Research Ethics Service (16/NW/0274).  93 
Identification of anticholinergic scales 94 
Ten different scales quantifying ACB were identified through systematic literature review19 (see 95 
supplementary appendix):  Anticholinergic Drug Scale (ADS),8 Clinician-rated Anticholinergic Scale 96 
(CrAS),5 Anticholinergic Risk Scale (ARS),4 Anticholinergic Cognitive Burden (ACoB),3 Anticholinergic 97 
Activity Scale (AAS),6 revised Anticholinergic Activity Scale (AAS-r),7 Anticholinergic Loading Scale 98 
(ALS),9 Modified Anticholinergic Risk Scale (m-ARS),12 Anticholinergic Effect on Cognition (AEC),10 99 
Anticholinergic Impregnation Scale (AIS).11  100 
Baseline variables 101 
All participants reported medications taken at the time of recruitment during an interview with a 102 
trained study nurse. Participants were asked to name all “regular medications” taken, excluding 103 
“short-term medications” (http://biobank.ctsu.ox.ac.uk/crystal/label.cgi?id=100075). Specific data 104 
on dose, formulation and duration were not collected. The British National Formulary was used to 105 
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identify generic and branded names for each medication.20 We calculated each participant’s ACB at 106 
baseline using each of the identified scales. Weightings for each medication (0-3) were taken from 107 
the published description of each scale, and then summed to give a numerical value for each scale. 108 
The following baseline variables were used in adjusted analyses: age; sex; socioeconomic status 109 
(Townsend score derived from participant postcodes); body mass index (BMI) (categorised into 110 
<18.5, 18.5-24.9, 25.0-29.9, ≥30.0); smoking (current, ex-, and non-smoker); alcohol frequency 111 
(never/special occasions only; one to three times/month; one to four times/week; daily/almost 112 
daily) and physical activity (classified into levels of physical activity in the last four weeks: none; low 113 
(light ‘DIY’ activity only); medium (heavy DIY and/or walking for pleasure and/or other exercises); 114 
and high (strenuous sports). Participants also reported morbidities at the baseline assessment. The 115 
morbidities described in this paper were taken from a list of 43 morbidities originally established for 116 
a large epidemiological study in Scotland and subsequently amended for UK Biobank.21,22 Number of 117 
morbidities reported were summed to give a morbidity count. 118 
 119 
Outcomes 120 
All outcomes were identified prospectively using data linkage. Baseline data were linked to national 121 
mortality records and hospital episode statistics (HES). HES outcomes were identified using ICD-10 122 
diagnostic codes.  Median follow-up 74.7 months (interquartile range 66.1 to 81.7).  123 
Primary outcome: 124 
 Composite outcome: all-cause mortality or Major Adverse Cardiovascular Event (MACE) (defined 125 
as non-fatal MI (I21), non-fatal stroke (I63, I64), or cardiovascular death (primary cause of death 126 
coded “I”) 127 
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Secondary outcomes 129 
 All-cause mortality 130 
 MACE 131 
 Hospital admission with fall (W0, W1) or fracture (S02, S12, S22, S32, S42, S52, S62, S72, S82, 132 
S92, T05) 133 
 Hospital admission with dementia or delirium (F00, F01, F02, F03, F05) (analysis limited to 134 
participants without a dementia diagnosis at baseline) 135 
Statistical analysis 136 
All analyses were pre-specified prior to inspection of the data in keeping with STROBE guidelines.23  137 
Baseline descriptive analysis 138 
We divided the cohort into participants taking any anticholinergic medication at baseline according 139 
to any of the ten scales, and those taking no anticholinergic medication. Age, sex, socioeconomic 140 
status, smoking, BMI, alcohol frequency, morbidity count, and number of medications were 141 
summarised for each group. 142 
Time-to-event analyses – main analysis 143 
We used Cox proportional hazard models to assess the risk of each outcome for baseline values of 144 
each of the anticholinergic scales. We examined log-log survival curves to assess the proportional 145 
hazards assumption for each variable. Cause specific-models were used to account for competing 146 
risks.24 Each outcome was modelled using time to first event.  147 
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For the main analysis, hazard ratios with 95% confidence intervals were calculated for a one-point 148 
increase in ACB for each scale. We excluded participants with missing data for one or more 149 
covariates. Each scale was modelled separately using three different models: 150 
 Model 1: Adjusted for age, sex, and socioeconomic status (n=501,992, 0.1% missing) 151 
 Model 2: Model 1 plus adjustment for BMI, smoking, alcohol frequency and physical activity 152 
(n=487,697, 3% missing) 153 
 Model 3:  Model 2 plus adjustment for morbidity count (n=483,182, 3% missing) 154 
 155 
Contribution of the anticholinergic scale was assessed by calculating the proportion of explainable 156 
variance explained by the scale. The predictive accuracy of model 3 was assessed using Harrell’s C-157 
statistic with ten-fold internal cross-validation. The C-statistic of a base model (including all 158 
covariates except the anticholinergic scale) was calculated for comparison.  159 
Time-to-event analyses – sensitivity analyses 160 
We performed three pre-specified sensitivity analyses to assess potential sources of bias: 161 
1. Excluding events occurring in the first 12 months of follow-up (limits bias from reverse 162 
causality) 163 
2. Follow-up truncated at 24 months, with participants censored at first event or 24 months 164 
follow-up, whichever happened first (to limit bias from unmeasured fluctuations in ACB over 165 
the full follow up period) 166 
3. Model adjusted for all covariates of model 2 plus hypertension, coronary heart disease, 167 
diabetes, stroke/transient ischaemic attack, and heart failure at baseline. For primary 168 
outcome (cardiovascular event or death), all-cause mortality, and MACE  169 
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Assessment of overlap of anticholinergic scales 170 
A Venn diagram was constructed using the four most frequently validated scales (ARS, ADS, CrAS, 171 
ACB 13) to assess the level of overlap in participants identified scoring 1 or more in these scales.3-5,8,13  172 
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Results 173 
Baseline characteristics 174 
Sociodemographic characteristics are shown in Table 1. Participants taking anticholinergic 175 
medication were significantly older, more likely to be female, to be current or ex-smokers, to report 176 
infrequent or no alcohol intake, and to have low physical activity. Median morbidity count was 177 
higher in those with higher ACB, as was median number of medications.  178 
ACB in UK Biobank participants 179 
Figure 1 shows the ACB in UK Biobank participants using each of the ten scales. There was variation 180 
between scales in the number of people identified at all levels. The ALS identified the highest 181 
number of people as taking anticholinergic medication (n=88,409, 17.6%). The ARS identified the 182 
fewest (n=40,298, 8.0%).  183 
Outcomes 184 
Primary outcome: MACE or Death (composite outcome) 185 
A total of 16,375 (3%) participants experienced either non-fatal MI, stroke, or died within the follow-186 
up period. Higher ACB was significantly associated with a higher risk of the primary outcome for all 187 
scales (table 2). The effect size associated with ACB was attenuated when adjusting for potential 188 
confounders (supplementary appendix). In the fully adjusted model (adjusted age, sex, 189 
socioeconomic status, BMI, smoking, alcohol, physical activity and morbidity count) hazard ratios per 190 
one-point increase in anticholinergic scale ranged from 1.05 (95% CI 1.03 to 1.07) for ARS to 1.12 191 
(1.11 to 1.14) for ADS. 192 
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Sensitivity analyses one (excluding events in the first year) and three (controlling for cardiovascular 193 
comorbidity) showed similar results to the main analysis. In sensitivity analysis two (truncated at 2 194 
years follow-up) ARS was not significantly associated with MACE or death.  195 
Secondary outcomes 196 
For each anticholinergic scale, hazard ratios from the fully adjusted model for each of the secondary 197 
outcomes are shown in table 2. 198 
When considering all-cause mortality and MACE separately, results were similar to the composite 199 
primary outcome. 200 
Each scale was significantly associated with risk of fall/fracture. But the predictive accuracy was 201 
lower than for other outcomes (e.g. C-statistic 0.626 with ADS, see supplementary appendix). 202 
Two hundred and ten participants (not reporting dementia at baseline) had a hospital admission 203 
with dementia or delirium during follow-up. Each scale was significantly associated with increased 204 
risk (table 2). The AEC score, which was designed to assess risk of neurocognitive complications, 205 
showed the greatest effect size for this outcome (HR 1.45, 95% CI 1.30 to 1.61). Models including 206 
AEC had the highest predictive accuracy for dementia/delirium compared to the base model (C-207 
statistic 0.832 and 0.806, respectively). HRs for ARS and AAS-r scales were no longer significant after 208 
excluding admissions in the first year. Truncating follow-up at 2 years, AAS-r did not show significant 209 
effect sizes (supplementary appendix). 210 
Overlap of populations identified by scales 211 
To illustrate the degree of overlap in populations identified as at risk by different scales, participants 212 
scoring ≥1 on any of the four most validated scales (ADS, CrAS, ARS and ACB)3-5,8 are included in 213 
Figure 2. Only 23% of these participants scored ≥1 on all four scales.   214 
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Discussion 215 
Summary of findings 216 
We demonstrate that there is considerable variability between scales in the proportion of 217 
participants identified as taking anticholinergic medication and the quantification of ACB. Regarding 218 
the four most validated scales,3-5,8 less than one in four of those scoring ≥1 in any scale were 219 
identified by all four scales. Despite this, a modest association between anticholinergic medication 220 
use and cardiovascular events, mortality, admission due to fall/fracture or dementia/delirium was 221 
seen across all scales after adjusting for multiple clinical and sociodemographic factors. Small effect 222 
sizes of this kind may still be important at the population level, especially when there is no 223 
proven intervention that halts or delays cognitive decline, one of the important adverse 224 
effects. The association between ACB and outcomes has biological plausibility. Our results seem 225 
robust, as associations remained consistent when corrected for potential confounders and across 226 
several pre-specified sensitivity analyses. Effect sizes for AEC and AIS, which were developed to 227 
predict neurocognitive outcomes, were higher for dementia/delirium, however confidence intervals 228 
overlapped with the other scales. While there is a consistent association between ACB and risk of 229 
adverse outcomes, regardless of scale used, the populations identified as being at risk vary 230 
considerably depending on which scale is used. This has important implications if ACB is to be 231 
assessed in clinical practice and interventions designed to reduce its impact. 232 
Strengths and limitations 233 
The UK Biobank cohort is larger than any previous cohort assessing ACB and includes data covering a 234 
wide range of sociodemographic and lifestyle characteristics. Follow-up through linkage to national 235 
HES and mortality registers limits recall bias in outcome assessment, but relies on these events 236 
resulting in an inpatient episode and being accurately coded. While this is unlikely to impact our 237 
identification of MACE, mortality and fractures, other outcomes such as falls and dementia/delirium 238 
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may lack sensitivity.25 While the length of follow-up is an advantage, ACB and the extent of 239 
multimorbidity may change over time. These changes are not captured by modelling only baseline 240 
values. We conducted a sensitivity analysis, truncating follow-up at two years, to limit bias caused by 241 
unmeasured fluctuations in ACB or multimorbidity over the follow-up period. However, such an 242 
analysis may only partially mitigate potential bias from unmeasured changes over time. All 243 
medication and morbidity variables were defined by self-report, which is a potential source of bias. 244 
UK Biobank data are not currently linked to primary care or prescribing databases that could validate 245 
medication use or diagnoses. However participants were supported by a study nurse in providing 246 
accurate medical and drug history, and limitations of self-report would be expected to impact each 247 
scale similarly.  Finally, we did not have information on dosage or duration of anticholinergic 248 
medication taken. The included scales do not specify medication dose, however this meant we were 249 
unable to include alterative scales such as the Drug Burden Index, which includes a sub-scale 250 
assessing ACB.26 Duration of medication usage is also likely to be an important factor in risk of 251 
adverse outcomes, and we were not able to measure this in our study.  252 
Our findings indicate association only. A causal relationship between ACB and adverse outcomes is 253 
not proven. Our findings, like any observational study, are susceptible to residual confounding. 254 
Assessing adverse consequences from medication use is particularly susceptible to confounding by 255 
indication (the indicating illness, rather than medication, is the causative factor in adverse 256 
outcomes).27 We attempted to limit this by adjusting for morbidity count as a measure of chronic 257 
disease burden. Results remained significant, although hazard ratios were attenuated. We also 258 
conducted a sensitivity analysis for cardiovascular outcomes adjusting for a range of cardio-259 
metabolic comorbidities, with similar results. However, these analyses cannot rule out residual 260 
confounding. 261 
 262 
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Context and implications 263 
Recommendations to reduce ACB are starting to be included in clinical guidelines (e.g. for dementia 264 
or polypharmacy).28,29 Our findings indicate the number of people identified as being ‘at risk’ will 265 
vary depending on measures used (ALS identified more than twice as many people as ARS) and 266 
different scales will identify different people. ARS and ACoB had the highest effect size for the 267 
primary outcome, although point estimates for AEC and AIS were higher for neurocognitive 268 
outcomes. Rather than identifying an optimal scale, our findings highlight pitfalls and implications 269 
which should be considered when attempting to identify and reduce ACB. Simplicity and usability of 270 
scales is also relevant to clinical use. The importance of classes of medications, compared to high or 271 
low scores, should also be explored.30 272 
 273 
There is a need to explore the impact of reducing ACB at a population level, as existing interventions’ 274 
focus is limited to frail older people.31,32 The average age of UK Biobank participants is younger than 275 
previous cohorts validating these scales (mean ages generally >70 years, many conducted in nursing 276 
homes or palliative care settings). UK Biobank is more affluent and less multimorbid than the UK 277 
average.33 While this limits accurate inference regarding prevalence of ACB in the general 278 
population, relationships between exposures and outcomes remain valid. However, the effect sizes 279 
seen in our study were modest, and the impact of reducing ACB at an individual level is not clear. 280 
Furthermore, residual confounding – particularly confounding by indication – cannot be excluded as 281 
an explanation for the associations seen. Our findings that ACB is associated with various adverse 282 
outcomes, in a younger and relatively healthier population than previously studied, highlight that 283 
there may be value in interventions to reduce ACB at a population level as the absolute numbers of 284 
people potentially at risk is high. Developing such an intervention would require investigation of 285 
barriers and facilitators to optimising anticholinergic prescribing at a patient, professional and 286 
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organisational level.  However, there is also a need to understand what factors increase 287 
susceptibility to adverse effects of ACB (e.g. older age, frailty, etc.), and these should be identified.  288 
  289 
Conclusion 290 
In a middle-older aged population of >500,000 people we demonstrate levels of anticholinergic 291 
prescribing ranging from 7.0% to 17.6% depending on the scale used.  There was an association of 292 
anticholinergic medication use with cardiovascular events, mortality, falls, fractures and 293 
dementia/delirium admissions irrespective of scale used. This was true after adjusting for 294 
sociodemographic factors and morbidities. However, different populations will be identified 295 
depending on the scale used. These findings should inform their use in clinical practice and in 296 
decision making in future intervention trials. 297 
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Table 1: Baseline characteristics 
Variable Score = 0 on all scales 
N = 367,319 
Score 1 or more on any scale 
N = 135,321 
Age (median, IQR) 
Missing 
57 (IQR: 49-62) 
0 
60 (IQR: 53-65) 
0 
Sex (%) 
Female 
Male 
Missing 
 
198,346 (54%) 
168,973 (46% 
0 
 
75,120 (55.5%) 
60,201 (44.5%) 
0 
Townsend score quintile 
(socioeconomic status) (%) 
1 (least deprived) 
2 
3 
4 
5 (most deprived) 
Missing 
Townsend score quintile 
(socioeconomic status) (%) 
77,293 (21.1.%) 
75,738 (20.6%) 
74,334 (20.3%) 
72,916 (19.9%) 
66,602 (18.2%) 
436 
Townsend score quintile 
(socioeconomic status) (%) 
23,394 (17.3%) 
24,381 (18.0%) 
26,078 (19.3%) 
27,479 (20.3%) 
33,798 (25.0%) 
191 
BMI category (%) 
<18.5 
18.5-24.9 
25.0-29.9 
≥30 
Missing 
 
1975 (0.5%) 
127,500 (35%) 
179,715 (43.8%) 
74,969 (20.6%) 
3,080 
 
651 (0.5%) 
29,887 (22.5%) 
54,552 (41.1%) 
47,491 (35.8%) 
2,740 
 20 
Smoking status (%) 
Never 
Previous 
Current 
Missing 
 
208,977 (57.2%) 
120,154 (32.9%) 
36,210 (9.9%) 
1,978 
 
64,624 (48.1%) 
52,944 (39.4%) 
16,779 (12.5%) 
974 
Alcohol frequency (%) 
Never/special occasions 
1-3 times per month 
1-4 times per week 
Daily/almost daily 
Missing 
 
61,230 (16.7%) 
39,987 (10.9%) 
187,445 (51.2%) 
77,572 (21.2%) 
1,085 
 
37,460 (27.8%) 
15.886 (11.0%) 
57,339 (42.5%) 
24,218 (18.0%) 
418 
Physical activity (%) 
High 
Medium 
Low 
None 
Missing 
 
43,279 (11.9%) 
290,383 (80.0) 
11,330 (3.1%) 
17,983 (5.0%) 
4,344 
 
6,798 (5.1%) 
103,221 (77.9%) 
7,613 (5.7%) 
14,875 (11.2%) 
2,814 
Number of comorbid 
conditions (median, IQR) 
Missing 
1 (IQR: 0-1) 
………………………………… 
1,173 
2 (IQR: 1-3) 
……………………………… 
672 
Total number of regular 
medications (median, IQR) 
Missing 
1 (IQR: 0-2) 
………………………………  
862 
4 (IQR: 3-7) 
……………………………… 
Missing 
 403 
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Table 2: Hazard ratio (and 95% confidence interval) of anticholinergic scales with outcomes.  
scales MACE/mortality All-cause 
mortality 
MACE Fall or fracture Dementia/deliri
um 
CrAS 1.05  
(1.03 to 1.07) 
1.05  
(1.04 to 1.07) 
1.03  
(1.0 to 1.06) 
1.09  
(1.06 to 1.11) 
1.23  
(1.1 to 1.36) 
ARS 1.05 
(1.03 to 1.08) 
1.06  
(1.04 to 1.08) 
1.01  
(0.97 to 1.05) 
1.06  
(1.03 to 1.10) 
1.23  
(1.07 to 1.40) 
AAS-r 1.06  
(1.04 to 1.08) 
1.07  
(1.05 to 1.08) 
1.07  
(1.04 to 1.09) 
1.09  
(1.06 to 1.12) 
1.14  
(1.02 to 1.28) 
ALS 1.06 
(1.04 to 1.08) 
1.07  
(1.05 to 1.08) 
1.04  
(1.01 to 1.07) 
1.1 
(1.07 to 1.13) 
1.26 
(1.14 to 1.41) 
AAS 1.06 
(1.05 to 1.08) 
1.07  
(1.05 to 1.09) 
1.07  
(1.05 to 1.10) 
1.09 
(1.06 to 1.12) 
1.24  
(1.11 to 1.37) 
AEC 1.07  
(1.05 to 1.10) 
1.08 (1.06 to 
1.10) 
1.04  
(1.00 to 1.08) 
1.12  
(1.09 to 1.16) 
1.45  
(1.30 to 1.61) 
m-ARS 1.07  
(1.06 to 1.09) 
1.08  
(1.06 to 1.10) 
1.02  
(0.99 to 1.06) 
1.08  
(1.05 to 1.12) 
1.27  
(1.13 to 1.43) 
AIS 1.08  
(1.06 to 1.10) 
1.09  
(1.07 to 1.11) 
1.04  
(1.01 to 1.08) 
1.14  
(1.1 to 1.17) 
1.38  
(1.24 to 1.54) 
ACoB 1.12  
(1.10 to 1.14) 
1.13  
(1.11 to 1.15) 
1.17  
(1.14 to 1.20) 
1.11  
(1.08 to 1.14) 
1.26  
(1.14 to 1.40) 
ADS 1.12  
(1.11 to 1.14) 
1.13  
(1.12 to 1.15) 
1.15  
(1.12 to 1.17) 
1.13  
(1.10 to 1.16) 
1.29  
(1.16 to 1.42) 
Results from model 3: Adjusted for age, sex, socioeconomic status, BMI, smoking, alcohol, 
physical activity, and morbidity count.  
 405 
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 407 
ARS Anticholinergic risk scale (Rudolph 2008) 49 included medications 
AEC Anticholinergic effect on cognition(Bishara 2016) 122 included medications 
mARS Modified anticholinergic risk scale (SCPG 2015) 61 included medications 
AIS Anticholinergic impregnation scale (Briet 2017) 128 included medications 
AAS-r Revised anticholinergic activity scale (Ehrt 2010) 99 included medications 
AAS Anticholinergic activity scale (Chew 2008) 107 included medications 
ACoB Anticholinergic cognitive burden (Boustani 2008) 88 included medications 
ADS Anticholinergic drug scale (Carnahan 2006) 117  included medications 
CrAS Clinician-rated anticholinergic scale (Han 2008) 60 included medications 
ALS Anticholinergic loading scale (Sittironnarit 2011) 49 included medications 
 408 
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Figure 2: Venn diagram of participants scoring ‘1 or more’ on any of the four most validated scales 410 
 411 
 412 
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Main analysis 442 
 443 
 444 
 445 
 446 
Hazard ratios per one-point increase in scale 447 
Model 1 - Adjusted for age, sex, and socioeconomic status 448 
scales MACE/mortality All-cause mortality MACE Fall or fracture Dementia/delirium 
ARS 1.21 ( 1.19 to 1.23 ) 1.22 ( 1.2 to 1.24 ) 1.21 ( 1.17 to 1.25 ) 1.15 ( 1.12 to 1.19 ) 1.38 ( 1.23 to 1.55 ) 
CrAS 1.21 ( 1.2 to 1.23 ) 1.22 ( 1.2 to 1.24 ) 1.25 ( 1.22 to 1.27 ) 1.17 ( 1.14 to 1.19 ) 1.36 ( 1.24 to 1.49 ) 
AAS-r 1.22 ( 1.2 to 1.23 ) 1.22 ( 1.21 to 1.24 ) 1.27 ( 1.25 to 1.3 ) 1.17 ( 1.15 to 1.2 ) 1.28 ( 1.17 to 1.41 ) 
AAS 1.23 ( 1.22 to 1.25 ) 1.24 ( 1.22 to 1.25 ) 1.29 ( 1.27 to 1.32 ) 1.17 ( 1.15 to 1.2 ) 1.39 ( 1.28 to 1.51 ) 
m-ARS 1.24 ( 1.22 to 1.25 ) 1.24 ( 1.23 to 1.26 ) 1.23 ( 1.2 to 1.27 ) 1.17 ( 1.14 to 1.2 ) 1.41 ( 1.28 to 1.56 ) 
ALS 1.24 ( 1.23 to 1.26 ) 1.25 ( 1.23 to 1.26 ) 1.28 ( 1.25 to 1.31 ) 1.18 ( 1.16 to 1.21 ) 1.41 ( 1.29 to 1.53 ) 
AIS 1.26 ( 1.24 to 1.28 ) 1.27 ( 1.25 to 1.29 ) 1.28 ( 1.24 to 1.31 ) 1.24 ( 1.21 to 1.27 ) 1.51 ( 1.38 to 1.66 ) 
AEC 1.26 ( 1.24 to 1.29 ) 1.27 ( 1.25 to 1.3 ) 1.28 ( 1.25 to 1.32 ) 1.23 ( 1.2 to 1.27 ) 1.61 ( 1.47 to 1.77 ) 
ACOB 1.28 ( 1.27 to 1.3 ) 1.29 ( 1.28 to 1.31 ) 1.38 ( 1.35 to 1.4 ) 1.21 ( 1.18 to 1.24 ) 1.43 ( 1.32 to 1.55 ) 
ADS 1.29 ( 1.28 to 1.31 ) 1.3 ( 1.29 to 1.32 ) 1.37 ( 1.34 to 1.39 ) 1.22 ( 1.2 to 1.25 ) 1.43 ( 1.32 to 1.55 ) 
Model 2 - adjusted for age, sex, socioeconomic status, BMI, smoking, alchohol and 449 
phyiscal activity 450 
scales MACE/mortality All-cause mortality MACE Fall or fracture Dementia/delirium 
ARS 1.14 ( 1.12 to 1.16 ) 1.14 ( 1.12 to 1.17 ) 1.11 ( 1.08 to 1.15 ) 1.12 ( 1.08 to 1.16 ) 1.34 ( 1.18 to 1.52 ) 
CrAS 1.14 ( 1.12 to 1.16 ) 1.15 ( 1.13 to 1.16 ) 1.14 ( 1.11 to 1.17 ) 1.14 ( 1.12 to 1.17 ) 1.34 ( 1.21 to 1.47 ) 
AAS-r 1.14 ( 1.13 to 1.16 ) 1.15 ( 1.13 to 1.17 ) 1.17 ( 1.14 to 1.2 ) 1.14 ( 1.12 to 1.17 ) 1.26 ( 1.14 to 1.4 ) 
AAS 1.15 ( 1.14 to 1.17 ) 1.16 ( 1.15 to 1.18 ) 1.19 ( 1.16 to 1.21 ) 1.15 ( 1.12 to 1.17 ) 1.35 ( 1.23 to 1.48 ) 
ALS 1.16 ( 1.14 to 1.18 ) 1.17 ( 1.15 to 1.19 ) 1.17 ( 1.14 to 1.2 ) 1.16 ( 1.13 to 1.19 ) 1.38 ( 1.25 to 1.52 ) 
m-ARS 1.16 ( 1.14 to 1.18 ) 1.17 ( 1.15 to 1.19 ) 1.13 ( 1.1 to 1.17 ) 1.14 ( 1.11 to 1.17 ) 1.38 ( 1.24 to 1.54 ) 
AEC 1.17 ( 1.15 to 1.19 ) 1.18 ( 1.16 to 1.2 ) 1.16 ( 1.12 to 1.2 ) 1.19 ( 1.15 to 1.23 ) 1.57 ( 1.42 to 1.73 ) 
AIS 1.18 ( 1.16 to 1.2 ) 1.19 ( 1.17 to 1.21 ) 1.16 ( 1.12 to 1.2 ) 1.2 ( 1.17 to 1.23 ) 1.5 ( 1.35 to 1.66 ) 
ACOB 1.21 ( 1.19 to 1.22 ) 1.22 ( 1.2 to 1.24 ) 1.27 ( 1.24 to 1.3 ) 1.17 ( 1.15 to 1.2 ) 1.38 ( 1.26 to 1.51 ) 
ADS 1.21 ( 1.2 to 1.23 ) 1.22 ( 1.21 to 1.24 ) 1.25 ( 1.23 to 1.28 ) 1.19 ( 1.16 to 1.21 ) 1.4 ( 1.28 to 1.53 ) 
Model 3 - adjuted for age, sex, socioeconomic status, BMI, smoking, alchohol, 451 
physical activity and number of long-term conditions 452 
scales MACE/mortality All-cause mortality MACE Fall or fracture Dementia/delirium 
CrAS 1.05 ( 1.03 to 1.07 ) 1.05 ( 1.04 to 1.07 ) 1.03 ( 1 to 1.06 ) 1.09 ( 1.06 to 1.11 ) 1.23 ( 1.1 to 1.36 ) 
ARS 1.05 ( 1.03 to 1.08 ) 1.06 ( 1.04 to 1.08 ) 1.01 ( 0.97 to 1.05 ) 1.06 ( 1.03 to 1.1 ) 1.23 ( 1.07 to 1.4 ) 
AAS-r 1.06 ( 1.04 to 1.08 ) 1.07 ( 1.05 to 1.08 ) 1.07 ( 1.04 to 1.09 ) 1.09 ( 1.06 to 1.12 ) 1.14 ( 1.02 to 1.28 ) 
ALS 1.06 ( 1.04 to 1.08 ) 1.07 ( 1.05 to 1.08 ) 1.04 ( 1.01 to 1.07 ) 1.1 ( 1.07 to 1.13 ) 1.26 ( 1.14 to 1.41 ) 
AAS 1.06 ( 1.05 to 1.08 ) 1.07 ( 1.05 to 1.09 ) 1.07 ( 1.05 to 1.1 ) 1.09 ( 1.06 to 1.12 ) 1.24 ( 1.11 to 1.37 ) 
AEC 1.07 ( 1.05 to 1.1 ) 1.08 ( 1.06 to 1.1 ) 1.04 ( 1 to 1.08 ) 1.12 ( 1.09 to 1.16 ) 1.45 ( 1.3 to 1.61 ) 
m-ARS 1.07 ( 1.06 to 1.09 ) 1.08 ( 1.06 to 1.1 ) 1.02 ( 0.99 to 1.06 ) 1.08 ( 1.05 to 1.12 ) 1.27 ( 1.13 to 1.43 ) 
AIS 1.08 ( 1.06 to 1.1 ) 1.09 ( 1.07 to 1.11 ) 1.04 ( 1.01 to 1.08 ) 1.14 ( 1.1 to 1.17 ) 1.38 ( 1.24 to 1.54 ) 
ACOB 1.12 ( 1.1 to 1.14 ) 1.13 ( 1.11 to 1.15 ) 1.17 ( 1.14 to 1.2 ) 1.11 ( 1.08 to 1.14 ) 1.26 ( 1.14 to 1.4 ) 
ADS 1.12 ( 1.11 to 1.14 ) 1.13 ( 1.12 to 1.15 ) 1.15 ( 1.12 to 1.17 ) 1.13 ( 1.1 to 1.16 ) 1.29 ( 1.16 to 1.42 ) 
 453 
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 454 
Predictive accuracy of fully adjusted model 455 
The predictive accuracy of model 3 was assessed using Harrell’s C-statistic with ten-fold internal 456 
cross-validation. C-statistic is an extension of the area under the curve for time-to-event data. A 457 
value of 1 indicates perfect prediction and a value of 0.5 no better than chance. The C-statistic of a 458 
base model (including all covariates except the anticholinergic scale) was calculated for comparison.  459 
C statistics for model 3 460 
scales MACE/mortality All-cause mortality MACE Fall or fracture Dementia/delirium 
Base model (add 
covariates minus 
anticholinergic 
score) 
0.737 0.741 0.757 0.623 0.820 
CrAS 0.737 0.741 0.757 0.624 0.822 
ARS 0.737 0.741 0.757 0.624 0.822 
AAS-r 0.737 0.741 0.757 0.625 0.822 
ALS 0.737 0.741 0.757 0.625 0.822 
AAS 0.737 0.741 0.757 0.625 0.822 
AEC 0.737 0.741 0.757 0.625 0.823 
m-ARS 0.737 0.741 0.757 0.624 0.823 
AIS 0.737 0.742 0.757 0.625 0.823 
ACOB 0.738 0.743 0.758 0.625 0.822 
ADS 0.738 0.742 0.758 0.626 0.822 
  461 
 27 
Sensitivity analysis 1: Excluding events occurring in the first 462 
12 months of follow-up (limits bias from reverse causality) 463 
Hazard ratios per one-point increase in scale 464 
Model 1 - Adjusted for age, sex, and socioeconomic status 465 
scales MACE/mortality All-cause mortality MACE Fall or fracture Dementia/delirium 
ARS 1.21 ( 1.19 to 1.23 ) 1.21 ( 1.19 to 1.24 ) 1.22 ( 1.17 to 1.26 ) 1.17 ( 1.13 to 1.22 ) 1.28 ( 1.1 to 1.49 ) 
CrAS 1.21 ( 1.2 to 1.23 ) 1.22 ( 1.2 to 1.23 ) 1.26 ( 1.23 to 1.29 ) 1.18 ( 1.15 to 1.21 ) 1.28 ( 1.14 to 1.44 ) 
AAS-r 1.22 ( 1.2 to 1.23 ) 1.22 ( 1.2 to 1.24 ) 1.29 ( 1.26 to 1.32 ) 1.18 ( 1.15 to 1.21 ) 1.26 ( 1.13 to 1.41 ) 
AAS 1.23 ( 1.21 to 1.24 ) 1.23 ( 1.22 to 1.25 ) 1.31 ( 1.28 to 1.34 ) 1.18 ( 1.15 to 1.21 ) 1.34 ( 1.22 to 1.49 ) 
ALS 1.24 ( 1.22 to 1.26 ) 1.24 ( 1.23 to 1.26 ) 1.3 ( 1.27 to 1.33 ) 1.2 ( 1.17 to 1.24 ) 1.33 ( 1.2 to 1.49 ) 
m-ARS 1.24 ( 1.22 to 1.26 ) 1.24 ( 1.22 to 1.26 ) 1.24 ( 1.2 to 1.28 ) 1.19 ( 1.15 to 1.23 ) 1.32 ( 1.16 to 1.5 ) 
AEC 1.26 ( 1.24 to 1.28 ) 1.27 ( 1.24 to 1.29 ) 1.3 ( 1.26 to 1.35 ) 1.25 ( 1.2 to 1.29 ) 1.5 ( 1.33 to 1.69 ) 
AIS 1.26 ( 1.24 to 1.28 ) 1.27 ( 1.25 to 1.29 ) 1.29 ( 1.26 to 1.33 ) 1.24 ( 1.2 to 1.28 ) 1.47 ( 1.31 to 1.65 ) 
ACOB 1.28 ( 1.26 to 1.3 ) 1.29 ( 1.27 to 1.3 ) 1.4 ( 1.37 to 1.43 ) 1.22 ( 1.19 to 1.26 ) 1.34 ( 1.2 to 1.49 ) 
ADS 1.29 ( 1.27 to 1.3 ) 1.3 ( 1.28 to 1.31 ) 1.39 ( 1.36 to 1.42 ) 1.24 ( 1.21 to 1.27 ) 1.36 ( 1.23 to 1.51 ) 
Model 2 - adjusted for age, sex, socioeconomic status, BMI, smoking, alchohol and 466 
phyiscal activity 467 
scales MACE/mortality All-cause mortality MACE Fall or fracture Dementia/delirium 
ARS 1.14 ( 1.12 to 1.16 ) 1.14 ( 1.12 to 1.17 ) 1.12 ( 1.08 to 1.17 ) 1.14 ( 1.1 to 1.19 ) 1.24 ( 1.05 to 1.46 ) 
CrAS 1.14 ( 1.12 to 1.16 ) 1.15 ( 1.13 to 1.16 ) 1.16 ( 1.13 to 1.19 ) 1.16 ( 1.12 to 1.19 ) 1.27 ( 1.12 to 1.43 ) 
AAS-r 1.14 ( 1.13 to 1.16 ) 1.15 ( 1.13 to 1.16 ) 1.19 ( 1.16 to 1.22 ) 1.15 ( 1.12 to 1.19 ) 1.24 ( 1.1 to 1.4 ) 
AAS 1.15 ( 1.14 to 1.17 ) 1.16 ( 1.14 to 1.17 ) 1.21 ( 1.18 to 1.24 ) 1.16 ( 1.13 to 1.2 ) 1.31 ( 1.17 to 1.47 ) 
ALS 1.16 ( 1.14 to 1.18 ) 1.17 ( 1.15 to 1.18 ) 1.19 ( 1.15 to 1.22 ) 1.19 ( 1.15 to 1.22 ) 1.31 ( 1.16 to 1.48 ) 
m-ARS 1.16 ( 1.14 to 1.18 ) 1.17 ( 1.15 to 1.19 ) 1.14 ( 1.1 to 1.18 ) 1.16 ( 1.12 to 1.2 ) 1.29 ( 1.13 to 1.49 ) 
AEC 1.17 ( 1.15 to 1.19 ) 1.17 ( 1.15 to 1.2 ) 1.18 ( 1.14 to 1.23 ) 1.21 ( 1.16 to 1.26 ) 1.47 ( 1.29 to 1.68 ) 
AIS 1.18 ( 1.16 to 1.2 ) 1.18 ( 1.16 to 1.2 ) 1.18 ( 1.14 to 1.22 ) 1.21 ( 1.17 to 1.25 ) 1.47 ( 1.3 to 1.66 ) 
ACOB 1.21 ( 1.19 to 1.22 ) 1.21 ( 1.2 to 1.23 ) 1.29 ( 1.26 to 1.32 ) 1.19 ( 1.15 to 1.22 ) 1.29 ( 1.14 to 1.45 ) 
ADS 1.21 ( 1.19 to 1.23 ) 1.22 ( 1.2 to 1.24 ) 1.28 ( 1.25 to 1.31 ) 1.21 ( 1.17 to 1.24 ) 1.32 ( 1.18 to 1.48 ) 
Model 3 - adjuted for age, sex, socioeconomic status, BMI, smoking, alchohol, 468 
physical activity and number of long-term conditions 469 
scales MACE/mortality All-cause mortality MACE Fall or fracture Dementia/delirium 
CrAS 1.06 ( 1.04 to 1.07 ) 1.06 ( 1.04 to 1.07 ) 1.04 ( 1.01 to 1.08 ) 1.1 ( 1.06 to 1.14 ) 1.15 ( 1 to 1.31 ) 
ARS 1.06 ( 1.04 to 1.08 ) 1.06 ( 1.04 to 1.08 ) 1.02 ( 0.98 to 1.06 ) 1.09 ( 1.04 to 1.13 ) 1.12 ( 0.94 to 1.33 ) 
AAS-r 1.06 ( 1.05 to 1.08 ) 1.06 ( 1.05 to 1.08 ) 1.09 ( 1.06 to 1.12 ) 1.1 ( 1.06 to 1.13 ) 1.11 ( 0.97 to 1.27 ) 
AAS 1.07 ( 1.05 to 1.08 ) 1.07 ( 1.05 to 1.09 ) 1.09 ( 1.06 to 1.13 ) 1.11 ( 1.07 to 1.14 ) 1.18 ( 1.04 to 1.34 ) 
ALS 1.07 ( 1.05 to 1.08 ) 1.07 ( 1.05 to 1.09 ) 1.06 ( 1.03 to 1.09 ) 1.12 ( 1.09 to 1.16 ) 1.18 ( 1.03 to 1.35 ) 
AEC 1.08 ( 1.05 to 1.1 ) 1.08 ( 1.06 to 1.1 ) 1.06 ( 1.02 to 1.1 ) 1.14 ( 1.1 to 1.19 ) 1.34 ( 1.16 to 1.54 ) 
m-ARS 1.08 ( 1.06 to 1.1 ) 1.08 ( 1.06 to 1.1 ) 1.03 ( 0.99 to 1.07 ) 1.1 ( 1.06 to 1.14 ) 1.18 ( 1.01 to 1.36 ) 
AIS 1.09 ( 1.07 to 1.11 ) 1.09 ( 1.07 to 1.11 ) 1.06 ( 1.02 to 1.1 ) 1.14 ( 1.1 to 1.19 ) 1.35 ( 1.18 to 1.54 ) 
ACOB 1.12 ( 1.1 to 1.14 ) 1.13 ( 1.11 to 1.14 ) 1.19 ( 1.16 to 1.22 ) 1.13 ( 1.09 to 1.16 ) 1.15 ( 1 to 1.32 ) 
ADS 1.13 ( 1.11 to 1.14 ) 1.13 ( 1.11 to 1.15 ) 1.17 ( 1.14 to 1.2 ) 1.15 ( 1.11 to 1.18 ) 1.19 ( 1.05 to 1.35 ) 
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Sensitivity analysis 2: Follow-up truncated at 24 months, 471 
with participants censored at first event or 24 months follow-472 
up, whichever happened first (to limit bias from unmeasured 473 
change in anticholinergic burden) 474 
Hazard ratios per one-point increase in scale 475 
Model 1 - Adjusted for age, sex, and socioeconomic status 476 
scales MACE/mortality All-cause mortality MACE Fall or fracture Dementia/delirium 
ARS 1.23 ( 1.18 to 1.27 ) 1.23 ( 1.18 to 1.28 ) 1.19 ( 1.13 to 1.25 ) 1.13 ( 1.09 to 1.18 ) 1.38 ( 1.18 to 1.61 ) 
CrAS 1.24 ( 1.21 to 1.27 ) 1.26 ( 1.23 to 1.3 ) 1.21 ( 1.16 to 1.25 ) 1.15 ( 1.12 to 1.18 ) 1.35 ( 1.19 to 1.52 ) 
m-ARS 1.24 ( 1.21 to 1.28 ) 1.26 ( 1.21 to 1.31 ) 1.2 ( 1.15 to 1.26 ) 1.15 ( 1.12 to 1.19 ) 1.42 ( 1.24 to 1.62 ) 
AAS-r 1.25 ( 1.22 to 1.28 ) 1.28 ( 1.24 to 1.31 ) 1.24 ( 1.2 to 1.28 ) 1.17 ( 1.14 to 1.2 ) 1.27 ( 1.12 to 1.44 ) 
AAS 1.26 ( 1.23 to 1.29 ) 1.3 ( 1.26 to 1.33 ) 1.24 ( 1.2 to 1.29 ) 1.16 ( 1.13 to 1.19 ) 1.39 ( 1.24 to 1.55 ) 
ALS 1.26 ( 1.23 to 1.3 ) 1.29 ( 1.25 to 1.33 ) 1.23 ( 1.18 to 1.27 ) 1.17 ( 1.14 to 1.2 ) 1.39 ( 1.23 to 1.56 ) 
AIS 1.3 ( 1.26 to 1.34 ) 1.33 ( 1.29 to 1.38 ) 1.23 ( 1.17 to 1.29 ) 1.23 ( 1.19 to 1.27 ) 1.52 ( 1.35 to 1.72 ) 
AEC 1.31 ( 1.27 to 1.35 ) 1.34 ( 1.29 to 1.39 ) 1.25 ( 1.19 to 1.31 ) 1.22 ( 1.18 to 1.27 ) 1.65 ( 1.47 to 1.86 ) 
ACOB 1.33 ( 1.3 to 1.36 ) 1.35 ( 1.32 to 1.39 ) 1.32 ( 1.28 to 1.36 ) 1.2 ( 1.17 to 1.23 ) 1.47 ( 1.33 to 1.63 ) 
ADS 1.33 ( 1.31 to 1.36 ) 1.38 ( 1.34 to 1.41 ) 1.31 ( 1.26 to 1.35 ) 1.21 ( 1.18 to 1.24 ) 1.45 ( 1.31 to 1.61 ) 
Model 2 - adjusted for age, sex, socioeconomic status, BMI, smoking, alchohol and 477 
phyiscal activity 478 
scales MACE/mortality All-cause mortality MACE Fall or fracture Dementia/delirium 
ARS 1.14 ( 1.1 to 1.18 ) 1.14 ( 1.09 to 1.19 ) 1.1 ( 1.04 to 1.16 ) 1.09 ( 1.05 to 1.14 ) 1.33 ( 1.12 to 1.58 ) 
CrAS 1.15 ( 1.11 to 1.18 ) 1.17 ( 1.13 to 1.21 ) 1.1 ( 1.05 to 1.15 ) 1.12 ( 1.09 to 1.16 ) 1.31 ( 1.15 to 1.5 ) 
m-ARS 1.15 ( 1.12 to 1.19 ) 1.17 ( 1.12 to 1.21 ) 1.1 ( 1.05 to 1.16 ) 1.12 ( 1.08 to 1.16 ) 1.38 ( 1.2 to 1.58 ) 
AAS-r 1.16 ( 1.12 to 1.19 ) 1.19 ( 1.15 to 1.22 ) 1.13 ( 1.09 to 1.18 ) 1.13 ( 1.1 to 1.17 ) 1.25 ( 1.09 to 1.43 ) 
ALS 1.16 ( 1.13 to 1.2 ) 1.19 ( 1.15 to 1.23 ) 1.11 ( 1.07 to 1.16 ) 1.14 ( 1.11 to 1.18 ) 1.36 ( 1.2 to 1.55 ) 
AAS 1.17 ( 1.14 to 1.2 ) 1.2 ( 1.16 to 1.24 ) 1.14 ( 1.09 to 1.18 ) 1.13 ( 1.1 to 1.16 ) 1.36 ( 1.2 to 1.53 ) 
AIS 1.19 ( 1.15 to 1.23 ) 1.23 ( 1.18 to 1.28 ) 1.12 ( 1.06 to 1.18 ) 1.19 ( 1.15 to 1.23 ) 1.48 ( 1.29 to 1.7 ) 
AEC 1.2 ( 1.15 to 1.24 ) 1.22 ( 1.17 to 1.28 ) 1.13 ( 1.07 to 1.2 ) 1.18 ( 1.14 to 1.22 ) 1.59 ( 1.4 to 1.81 ) 
ACOB 1.23 ( 1.2 to 1.26 ) 1.26 ( 1.22 to 1.3 ) 1.21 ( 1.17 to 1.26 ) 1.16 ( 1.13 to 1.2 ) 1.42 ( 1.27 to 1.59 ) 
ADS 1.23 ( 1.2 to 1.26 ) 1.27 ( 1.24 to 1.31 ) 1.19 ( 1.15 to 1.24 ) 1.18 ( 1.14 to 1.21 ) 1.43 ( 1.28 to 1.6 ) 
Model 3 - adjuted for age, sex, socioeconomic status, BMI, smoking, alchohol, 479 
physical activity and number of long-term conditions 480 
scales MACE/mortality All-cause mortality MACE Fall or fracture Dementia/delirium 
CrAS 1.03 ( 1 to 1.07 ) 1.05 ( 1.01 to 1.09 ) 0.99 ( 0.94 to 1.04 ) 1.06 ( 1.03 to 1.1 ) 1.22 ( 1.05 to 1.41 ) 
ALS 1.04 ( 1 to 1.07 ) 1.06 ( 1.02 to 1.1 ) 0.99 ( 0.94 to 1.03 ) 1.08 ( 1.04 to 1.11 ) 1.26 ( 1.09 to 1.46 ) 
ARS 1.04 ( 1 to 1.08 ) 1.03 ( 0.98 to 1.08 ) 1 ( 0.95 to 1.06 ) 1.04 ( 0.99 to 1.08 ) 1.23 ( 1.03 to 1.48 ) 
m-ARS 1.05 ( 1.01 to 1.08 ) 1.05 ( 1 to 1.09 ) 1 ( 0.95 to 1.06 ) 1.06 ( 1.02 to 1.1 ) 1.28 ( 1.1 to 1.49 ) 
AAS-r 1.05 ( 1.02 to 1.08 ) 1.08 ( 1.04 to 1.11 ) 1.03 ( 0.99 to 1.07 ) 1.08 ( 1.05 to 1.11 ) 1.13 ( 0.97 to 1.32 ) 
AAS 1.05 ( 1.02 to 1.09 ) 1.08 ( 1.04 to 1.12 ) 1.02 ( 0.98 to 1.07 ) 1.07 ( 1.04 to 1.1 ) 1.25 ( 1.09 to 1.44 ) 
AEC 1.08 ( 1.04 to 1.12 ) 1.1 ( 1.05 to 1.15 ) 1.02 ( 0.96 to 1.08 ) 1.11 ( 1.07 to 1.16 ) 1.5 ( 1.3 to 1.72 ) 
AIS 1.08 ( 1.04 to 1.12 ) 1.1 ( 1.06 to 1.15 ) 1 ( 0.95 to 1.06 ) 1.12 ( 1.08 to 1.17 ) 1.38 ( 1.19 to 1.61 ) 
ACOB 1.12 ( 1.09 to 1.15 ) 1.14 ( 1.1 to 1.18 ) 1.11 ( 1.06 to 1.15 ) 1.1 ( 1.07 to 1.14 ) 1.33 ( 1.17 to 1.51 ) 
ADS 1.12 ( 1.09 to 1.15 ) 1.16 ( 1.12 to 1.2 ) 1.08 ( 1.04 to 1.13 ) 1.12 ( 1.08 to 1.15 ) 1.34 ( 1.17 to 1.52 ) 
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Sensitivity analysis 3: Model adjusted for all covariates of 481 
model 2 plus hypertension, coronary heart disease, diabetes, 482 
previous stroke/transient ischaemic attack, and heart failure 483 
at baseline, instead of adjusting for morbidity count. For 484 
primary outcome (cardiovascular event or death), all-cause 485 
mortality, and MACE 486 
Hazard ratios per one-point increase in scale 487 
scales MACE/mortality All-cause mortality MACE 
CrAS 1.1 ( 1.09 to 1.12 ) 1.11 ( 1.09 to 1.13 ) 1.06 ( 1.03 to 1.09 ) 
ARS 1.11 ( 1.09 to 1.14 ) 1.12 ( 1.1 to 1.14 ) 1.07 ( 1.03 to 1.11 ) 
AAS 1.11 ( 1.1 to 1.13 ) 1.12 ( 1.1 to 1.14 ) 1.1 ( 1.08 to 1.13 ) 
AAS-r 1.11 ( 1.1 to 1.13 ) 1.12 ( 1.11 to 1.14 ) 1.11 ( 1.09 to 1.14 ) 
ALS 1.12 ( 1.1 to 1.13 ) 1.13 ( 1.11 to 1.14 ) 1.09 ( 1.06 to 1.12 ) 
m-ARS 1.14 ( 1.12 to 1.16 ) 1.15 ( 1.13 to 1.17 ) 1.09 ( 1.05 to 1.12 ) 
AEC 1.15 ( 1.13 to 1.17 ) 1.16 ( 1.13 to 1.18 ) 1.11 ( 1.08 to 1.15 ) 
AIS 1.15 ( 1.13 to 1.17 ) 1.16 ( 1.14 to 1.18 ) 1.11 ( 1.08 to 1.15 ) 
ACOB 1.16 ( 1.14 to 1.18 ) 1.17 ( 1.16 to 1.19 ) 1.17 ( 1.14 to 1.2 ) 
ADS 1.17 ( 1.16 to 1.19 ) 1.19 ( 1.17 to 1.2 ) 1.17 ( 1.14 to 1.2 ) 
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Post-hoc analyses: 489 
 Excluding participants with a prior history of fall or fracture 490 
 491 
scales Fall/fracture 
CrAS 1.09 (1.05-1.12) 
ARS 1.06 (1.02-1.1) 
AAS 1.09 (1.06-1.12) 
AAS-r 1.09 (1.06-1.12) 
ALS 1.1 (1.07-1.14) 
m-ARS 1.08 (1.04-1.12) 
AEC 1.13 (1.09-1.17) 
AIS 1.13 (1.1-1.17) 
ACOB 1.11 (1.08-1.14) 
ADS 1.12 (1.09-1.15) 
 492 
Delirium as outcome, including participants with dementia at 493 
baseline 494 
 495 
scales Delirium 
CrAS 1.09 (1.05-1.14) 
ARS 1.12 (1.07-1.18) 
AAS 1.10 (1.06-1.14) 
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AAS-r 1.14 (1.10-1.18) 
ALS 1.11 (1.06-1.16) 
m-ARS 1.15 (1.10-1.20) 
AEC 1.20 (1.14-1.26) 
AIS 1.20 (1.15-1.25) 
ACOB 1.12 (1.07-1.16) 
ADS 1.12 (1.07-1.16) 
  496 
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Scales treated as categorical variables (score 1-2, and score 497 
≥3) 498 
The main analysis assessed the hazard ratio associated with one-point increase in each scale. We 499 
also analysed each scale as a categorical variable, the results of which are shown below. There is no 500 
generally accepted convention or cut-offs used to categorise anticholinergic scales. For consistency, 501 
we applied the same cut-offs to each scale: 502 
 Score 1 – 2 (low) 503 
 Score 3 or more 504 
A score of 0 was the reference group 505 
Hazard ratio for categorised scales 506 
Model 1 - Adjusted for age, sex, and socioeconomic status 507 
Primary outcome (MACE or death) 508 
scales Score 1 to 2 Score 3 or more 
AAS 1.83 ( 1.76 to 1.9 ) 2.17 ( 2.04 to 2.31 ) 
AAS-r 1.88 ( 1.8 to 1.97 ) 2.08 ( 1.96 to 2.21 ) 
ACOB 1.8 ( 1.73 to 1.87 ) 2.36 ( 2.23 to 2.49 ) 
ADS 1.89 ( 1.82 to 1.96 ) 2.55 ( 2.42 to 2.69 ) 
AEC 1.89 ( 1.79 to 1.98 ) 1.96 ( 1.83 to 2.1 ) 
AIS 1.88 ( 1.78 to 1.97 ) 2.01 ( 1.89 to 2.14 ) 
ALS 1.68 ( 1.62 to 1.74 ) 2.15 ( 2.03 to 2.28 ) 
ARS 1.52 ( 1.43 to 1.61 ) 1.88 ( 1.75 to 2.01 ) 
CrAS 1.54 ( 1.48 to 1.6 ) 2.04 ( 1.92 to 2.16 ) 
m-ARS 1.66 ( 1.58 to 1.74 ) 1.99 ( 1.86 to 2.12 ) 
All-cause mortality 509 
scales Score 1 to 2 Score 3 or more 
AAS 1.85 ( 1.78 to 1.93 ) 2.21 ( 2.07 to 2.36 ) 
AAS-r 1.93 ( 1.84 to 2.02 ) 2.11 ( 1.98 to 2.26 ) 
ACOB 1.82 ( 1.75 to 1.9 ) 2.43 ( 2.29 to 2.57 ) 
ADS 1.93 ( 1.86 to 2.01 ) 2.64 ( 2.49 to 2.79 ) 
AEC 1.92 ( 1.82 to 2.02 ) 2.01 ( 1.87 to 2.16 ) 
AIS 1.94 ( 1.84 to 2.04 ) 2.06 ( 1.93 to 2.2 ) 
ALS 1.71 ( 1.65 to 1.78 ) 2.19 ( 2.06 to 2.33 ) 
ARS 1.52 ( 1.43 to 1.62 ) 1.91 ( 1.77 to 2.05 ) 
CrAS 1.56 ( 1.5 to 1.63 ) 2.06 ( 1.93 to 2.19 ) 
m-ARS 1.68 ( 1.59 to 1.77 ) 2.03 ( 1.9 to 2.18 ) 
MACE 510 
scales Score 1 to 2 Score 3 or more 
AAS 2.34 ( 2.19 to 2.5 ) 2.69 ( 2.41 to 3 ) 
AAS-r 2.39 ( 2.22 to 2.58 ) 2.59 ( 2.32 to 2.88 ) 
ACOB 2.34 ( 2.19 to 2.5 ) 3.21 ( 2.92 to 3.52 ) 
ADS 2.21 ( 2.07 to 2.37 ) 3.38 ( 3.08 to 3.7 ) 
AEC 2.11 ( 1.92 to 2.31 ) 2.01 ( 1.77 to 2.29 ) 
AIS 1.99 ( 1.81 to 2.18 ) 2.07 ( 1.84 to 2.32 ) 
ALS 1.91 ( 1.79 to 2.05 ) 2.48 ( 2.22 to 2.76 ) 
ARS 1.52 ( 1.37 to 1.69 ) 1.9 ( 1.67 to 2.17 ) 
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CrAS 1.73 ( 1.61 to 1.85 ) 2.26 ( 2.02 to 2.51 ) 
m-ARS 1.62 ( 1.47 to 1.78 ) 1.99 ( 1.76 to 2.25 ) 
Fall or fracture 511 
scales Score 1 to 2 Score 3 or more 
AAS 1.55 ( 1.45 to 1.67 ) 1.77 ( 1.59 to 1.97 ) 
AAS-r 1.63 ( 1.51 to 1.76 ) 1.78 ( 1.6 to 1.98 ) 
ACOB 1.5 ( 1.4 to 1.61 ) 1.83 ( 1.66 to 2.01 ) 
ADS 1.72 ( 1.61 to 1.84 ) 1.9 ( 1.72 to 2.1 ) 
AEC 1.88 ( 1.73 to 2.04 ) 1.69 ( 1.5 to 1.9 ) 
AIS 1.93 ( 1.78 to 2.1 ) 1.75 ( 1.57 to 1.96 ) 
ALS 1.59 ( 1.49 to 1.7 ) 1.71 ( 1.54 to 1.9 ) 
ARS 1.39 ( 1.26 to 1.54 ) 1.55 ( 1.37 to 1.75 ) 
CrAS 1.49 ( 1.39 to 1.59 ) 1.67 ( 1.51 to 1.86 ) 
m-ARS 1.45 ( 1.32 to 1.58 ) 1.63 ( 1.45 to 1.83 ) 
Dementia or delirium 512 
scales Score 1 to 2 Score 3 or more 
AAS 2.38 ( 1.71 to 3.29 ) 4.46 ( 2.95 to 6.73 ) 
AAS-r 2.03 ( 1.4 to 2.93 ) 3.24 ( 2.08 to 5.04 ) 
ACOB 2.08 ( 1.51 to 2.86 ) 3.29 ( 2.17 to 5.01 ) 
ADS 2.24 ( 1.62 to 3.1 ) 4.1 ( 2.77 to 6.07 ) 
AEC 4.64 ( 3.31 to 6.52 ) 4.42 ( 2.81 to 6.94 ) 
AIS 4.93 ( 3.52 to 6.9 ) 3.97 ( 2.57 to 6.14 ) 
ALS 2.13 ( 1.55 to 2.93 ) 4.27 ( 2.84 to 6.42 ) 
ARS 2.36 ( 1.55 to 3.59 ) 2.52 ( 1.48 to 4.28 ) 
CrAS 2.2 ( 1.61 to 3.02 ) 3.63 ( 2.37 to 5.55 ) 
m-ARS 3.02 ( 2.11 to 4.33 ) 2.63 ( 1.57 to 4.42 ) 
Model 2 - Adjusted for age, sex, socioeconomic status, BMI, smoking, alcohol and 513 
physical activity 514 
Primary outcome (MACE or death) 515 
scales Score 1 to 2 Score 3 or more 
AAS 1.59 ( 1.53 to 1.66 ) 1.67 ( 1.57 to 1.79 ) 
AAS-r 1.64 ( 1.56 to 1.71 ) 1.61 ( 1.51 to 1.72 ) 
ACOB 1.59 ( 1.53 to 1.65 ) 1.86 ( 1.75 to 1.97 ) 
ADS 1.64 ( 1.57 to 1.71 ) 1.98 ( 1.86 to 2.09 ) 
AEC 1.63 ( 1.54 to 1.72 ) 1.5 ( 1.39 to 1.61 ) 
AIS 1.6 ( 1.51 to 1.69 ) 1.59 ( 1.48 to 1.7 ) 
ALS 1.46 ( 1.4 to 1.52 ) 1.65 ( 1.55 to 1.77 ) 
ARS 1.36 ( 1.28 to 1.44 ) 1.47 ( 1.36 to 1.59 ) 
CrAS 1.37 ( 1.31 to 1.42 ) 1.6 ( 1.51 to 1.71 ) 
m-ARS 1.45 ( 1.37 to 1.53 ) 1.56 ( 1.46 to 1.68 ) 
All-cause mortality 516 
scales Score 1 to 2 Score 3 or more 
AAS 1.62 ( 1.55 to 1.7 ) 1.7 ( 1.59 to 1.83 ) 
AAS-r 1.68 ( 1.61 to 1.77 ) 1.64 ( 1.53 to 1.76 ) 
ACOB 1.61 ( 1.54 to 1.68 ) 1.91 ( 1.8 to 2.03 ) 
ADS 1.68 ( 1.61 to 1.75 ) 2.05 ( 1.93 to 2.18 ) 
AEC 1.65 ( 1.56 to 1.75 ) 1.54 ( 1.42 to 1.66 ) 
AIS 1.64 ( 1.55 to 1.74 ) 1.62 ( 1.51 to 1.74 ) 
ALS 1.5 ( 1.43 to 1.56 ) 1.68 ( 1.57 to 1.8 ) 
ARS 1.37 ( 1.28 to 1.46 ) 1.49 ( 1.38 to 1.62 ) 
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CrAS 1.39 ( 1.33 to 1.45 ) 1.62 ( 1.52 to 1.74 ) 
m-ARS 1.47 ( 1.39 to 1.55 ) 1.6 ( 1.48 to 1.72 ) 
MACE 517 
scales Score 1 to 2 Score 3 or more 
AAS 1.9 ( 1.77 to 2.05 ) 1.91 ( 1.69 to 2.14 ) 
AAS-r 1.97 ( 1.82 to 2.14 ) 1.84 ( 1.64 to 2.07 ) 
ACOB 1.96 ( 1.83 to 2.11 ) 2.35 ( 2.12 to 2.6 ) 
ADS 1.84 ( 1.71 to 1.98 ) 2.41 ( 2.18 to 2.67 ) 
AEC 1.75 ( 1.59 to 1.93 ) 1.41 ( 1.23 to 1.63 ) 
AIS 1.62 ( 1.46 to 1.79 ) 1.49 ( 1.31 to 1.7 ) 
ALS 1.55 ( 1.44 to 1.66 ) 1.73 ( 1.54 to 1.95 ) 
ARS 1.32 ( 1.18 to 1.47 ) 1.37 ( 1.19 to 1.58 ) 
CrAS 1.44 ( 1.33 to 1.54 ) 1.63 ( 1.45 to 1.84 ) 
m-ARS 1.37 ( 1.24 to 1.51 ) 1.43 ( 1.25 to 1.64 ) 
Fall or fracture 518 
scales Score 1 to 2 Score 3 or more 
AAS 1.51 ( 1.4 to 1.63 ) 1.59 ( 1.41 to 1.79 ) 
AAS-r 1.53 ( 1.41 to 1.67 ) 1.61 ( 1.44 to 1.81 ) 
ACOB 1.46 ( 1.35 to 1.57 ) 1.63 ( 1.46 to 1.81 ) 
ADS 1.67 ( 1.56 to 1.79 ) 1.68 ( 1.51 to 1.88 ) 
AEC 1.78 ( 1.63 to 1.94 ) 1.49 ( 1.3 to 1.69 ) 
AIS 1.82 ( 1.67 to 1.98 ) 1.59 ( 1.41 to 1.79 ) 
ALS 1.57 ( 1.46 to 1.68 ) 1.56 ( 1.39 to 1.76 ) 
ARS 1.37 ( 1.24 to 1.52 ) 1.37 ( 1.2 to 1.56 ) 
CrAS 1.46 ( 1.36 to 1.56 ) 1.53 ( 1.37 to 1.72 ) 
m-ARS 1.41 ( 1.28 to 1.55 ) 1.45 ( 1.28 to 1.65 ) 
Dementia or delirium 519 
scales Score 1 to 2 Score 3 or more 
AAS 2.2 ( 1.54 to 3.15 ) 3.91 ( 2.48 to 6.16 ) 
AAS-r 1.85 ( 1.24 to 2.78 ) 3.03 ( 1.89 to 4.86 ) 
ACOB 1.98 ( 1.4 to 2.8 ) 2.88 ( 1.81 to 4.57 ) 
ADS 2.16 ( 1.52 to 3.07 ) 3.9 ( 2.55 to 5.98 ) 
AEC 4.28 ( 2.96 to 6.19 ) 4.15 ( 2.56 to 6.74 ) 
AIS 4.6 ( 3.19 to 6.64 ) 4.04 ( 2.56 to 6.38 ) 
ALS 2.01 ( 1.42 to 2.84 ) 3.99 ( 2.55 to 6.22 ) 
ARS 2.19 ( 1.4 to 3.44 ) 2.21 ( 1.24 to 3.93 ) 
CrAS 2.17 ( 1.55 to 3.05 ) 3.53 ( 2.24 to 5.57 ) 
m-ARS 2.96 ( 2.02 to 4.33 ) 2.37 ( 1.35 to 4.14 ) 
Model 3 - Adjusted for age, sex, socioeconomic status, BMI, smoking, alcohol, 520 
physical activity and number of long-term conditions 521 
Primary outcome (MACE or death) 522 
scales Score 1 to 2 Score 3 or more 
AAS 1.28 ( 1.22 to 1.34 ) 1.24 ( 1.16 to 1.33 ) 
AAS-r 1.32 ( 1.26 to 1.39 ) 1.22 ( 1.14 to 1.31 ) 
ACOB 1.32 ( 1.27 to 1.38 ) 1.44 ( 1.35 to 1.53 ) 
ADS 1.36 ( 1.3 to 1.42 ) 1.52 ( 1.43 to 1.62 ) 
AEC 1.29 ( 1.22 to 1.36 ) 1.18 ( 1.09 to 1.27 ) 
AIS 1.26 ( 1.19 to 1.33 ) 1.25 ( 1.17 to 1.34 ) 
ALS 1.18 ( 1.13 to 1.23 ) 1.22 ( 1.14 to 1.31 ) 
ARS 1.13 ( 1.06 to 1.2 ) 1.17 ( 1.08 to 1.26 ) 
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CrAS 1.13 ( 1.08 to 1.18 ) 1.21 ( 1.13 to 1.29 ) 
m-ARS 1.19 ( 1.13 to 1.26 ) 1.22 ( 1.14 to 1.32 ) 
All-cause mortality 523 
scales Score 1 to 2 Score 3 or more 
AAS 1.3 ( 1.24 to 1.36 ) 1.25 ( 1.16 to 1.35 ) 
AAS-r 1.35 ( 1.28 to 1.42 ) 1.24 ( 1.15 to 1.33 ) 
ACOB 1.34 ( 1.28 to 1.4 ) 1.47 ( 1.38 to 1.57 ) 
ADS 1.39 ( 1.33 to 1.46 ) 1.57 ( 1.47 to 1.68 ) 
AEC 1.3 ( 1.22 to 1.38 ) 1.2 ( 1.11 to 1.3 ) 
AIS 1.29 ( 1.22 to 1.37 ) 1.27 ( 1.18 to 1.37 ) 
ALS 1.21 ( 1.15 to 1.26 ) 1.23 ( 1.15 to 1.33 ) 
ARS 1.13 ( 1.05 to 1.2 ) 1.18 ( 1.09 to 1.28 ) 
CrAS 1.15 ( 1.1 to 1.2 ) 1.21 ( 1.13 to 1.3 ) 
m-ARS 1.2 ( 1.13 to 1.27 ) 1.24 ( 1.15 to 1.34 ) 
MACE 524 
scales Score 1 to 2 Score 3 or more 
AAS 1.47 ( 1.36 to 1.59 ) 1.32 ( 1.16 to 1.49 ) 
AAS-r 1.52 ( 1.4 to 1.66 ) 1.32 ( 1.17 to 1.49 ) 
ACOB 1.6 ( 1.48 to 1.72 ) 1.74 ( 1.56 to 1.94 ) 
ADS 1.47 ( 1.36 to 1.59 ) 1.75 ( 1.57 to 1.95 ) 
AEC 1.3 ( 1.17 to 1.43 ) 1.04 ( 0.9 to 1.2 ) 
AIS 1.19 ( 1.07 to 1.32 ) 1.09 ( 0.96 to 1.25 ) 
ALS 1.18 ( 1.1 to 1.28 ) 1.16 ( 1.02 to 1.32 ) 
ARS 1.04 ( 0.93 to 1.17 ) 1.02 ( 0.88 to 1.18 ) 
CrAS 1.14 ( 1.05 to 1.23 ) 1.13 ( 1 to 1.27 ) 
m-ARS 1.06 ( 0.96 to 1.17 ) 1.04 ( 0.9 to 1.19 ) 
Fall or fracture 525 
scales Score 1 to 2 Score 3 or more 
AAS 1.31 ( 1.21 to 1.42 ) 1.31 ( 1.16 to 1.49 ) 
AAS-r 1.33 ( 1.22 to 1.45 ) 1.35 ( 1.2 to 1.53 ) 
ACOB 1.29 ( 1.19 to 1.39 ) 1.38 ( 1.23 to 1.54 ) 
ADS 1.48 ( 1.38 to 1.6 ) 1.44 ( 1.29 to 1.62 ) 
AEC 1.53 ( 1.4 to 1.68 ) 1.28 ( 1.12 to 1.47 ) 
AIS 1.58 ( 1.44 to 1.73 ) 1.37 ( 1.21 to 1.55 ) 
ALS 1.38 ( 1.28 to 1.48 ) 1.32 ( 1.17 to 1.49 ) 
ARS 1.21 ( 1.09 to 1.35 ) 1.17 ( 1.02 to 1.34 ) 
CrAS 1.29 ( 1.2 to 1.39 ) 1.29 ( 1.14 to 1.45 ) 
m-ARS 1.23 ( 1.12 to 1.36 ) 1.23 ( 1.08 to 1.4 ) 
Dementia or delirium 526 
scales Score 1 to 2 Score 3 or more 
AAS 1.72 ( 1.18 to 2.51 ) 2.65 ( 1.61 to 4.35 ) 
AAS-r 1.4 ( 0.92 to 2.13 ) 2.01 ( 1.21 to 3.35 ) 
ACOB 1.53 ( 1.07 to 2.2 ) 2.05 ( 1.25 to 3.35 ) 
ADS 1.73 ( 1.2 to 2.5 ) 2.75 ( 1.73 to 4.38 ) 
AEC 3.33 ( 2.25 to 4.93 ) 3.3 ( 2 to 5.45 ) 
AIS 3.6 ( 2.44 to 5.32 ) 3.26 ( 2.03 to 5.24 ) 
ALS 1.56 ( 1.08 to 2.26 ) 2.86 ( 1.78 to 4.62 ) 
ARS 1.75 ( 1.1 to 2.77 ) 1.66 ( 0.92 to 2.98 ) 
CrAS 1.74 ( 1.22 to 2.48 ) 2.59 ( 1.6 to 4.19 ) 
m-ARS 2.38 ( 1.6 to 3.52 ) 1.79 ( 1.01 to 3.17 ) 
 35 
 527 
Categorisation of Long-Term Conditions 528 
Morbidity grouping* Conditions included 
Hypertension Hypertension 
Essential hypertension 
Coronary heart disease Heart attack/MI 
Angina 
Diabetes Diabetic nephropathy 
Diabetic neuropathy/ulcers 
Diabetes 
Type 1 diabetes 
Type 2 diabetes 
Diabetic eye disease 
Stroke/TIA Stroke 
TIA 
Subarachnoid haemorrhage 
Brain haemorrhage 
Ischaemic stroke 
Atrial fibrillation Atrial fibrillation 
Heart failure Cardiomyopathy 
Hypertrophic cardiomyopathy 
Heart failure/pulmonary oedema 
Peripheral vascular disease Peripheral vascular disease 
Leg claudication/intermittent claudication 
COPD COPD/Chronic obstructive pulmonary disease 
Emphysema/Chronic bronchitis 
Emphysema 
Asthma Asthma 
Bronchiectasis Bronchiectasis 
Cancer “yes”/”no” to “have you ever had cancer?” 
Dyspepsia Gastro-oesophageal reflux (GORD) 
Oesophagitis/Barrett’s oesophagus 
Gastric stomach ulcers 
Gastric erosions/gastritis 
Duodenal ulcer 
Dyspepsia/indigestion 
Hiatus hernia 
Helicobacter pylori 
Diverticular disease Diverticular disease/diverticulitis 
Irritable bowel syndrome Irritable bowel syndrome 
Chronic liver disease Oesophageal varices 
Non infective hepatitis 
Liver failure/cirrhosis 
Primary biliary cirrhosis 
Inflammatory bowel disease Inflammatory bowel disease 
Crohn’s disease 
Ulcerative colitis 
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Constipation Constipation 
Viral hepatitis Hepatitis B 
Hepatitis C 
Hepatitis D 
Depression Depression 
Postnatal depression 
Anxiety Anxiety/panic attacks 
Nervous breakdown 
Post-traumatic stress disorder 
Obsessive compulsive disorder 
Stress 
Insomnia 
Psychological/psychiatric problem 
Schizophrenia/Bipolar affective disorder 
Bipolar 
Scizophrenia 
Mania 
Bipolar disorder 
Manic depression 
Connective tissue diseases 
 
 
Myositis/myopathy 
Systemic lupus erythematosus/SLE 
Connective tissue disorder 
Sjogren’s syndrome.sicca syndrome 
Dermatopolymyositis 
Scloeroderma/systemic sclerosis 
Rheumatoid arthritis 
Psoriatic arthropathy 
Dermatomyositis 
Polymyositis 
Polymyalgia rheumatica 
Painful conditions Back pain 
Joint pain 
Headaches (not migraine) 
Sciatica 
Plantar fasciitis 
Carpal tunnel syndrome 
Fibromyalgia 
Arthritis 
Shingles 
Disc problem 
Prolapsed disc/slipped disc 
Spine arthritis/spondylitis 
Ankylosing spondylitis 
Back problem 
Osteoarthritis 
Gout 
Cervical spondylosis 
Trigeminal neuralgia 
Disc degeneration 
Trapped nerve/compressed nerve 
Osteoporosis Osteoporosis 
Thyroid disorders Thyroid problem (not cancer 
Hyperthroidism/thyrotoxicosis 
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Hypothyroidism/myxoedema 
Grave’s disease 
Thyroid goitre 
Thyroititis 
Alcohol problems Alcohol dependency 
Alcoholic liver disease/alcoholic cirrhosis 
Chronic kidney disease Polycystic kidney 
Diabetic nephropathy 
Renal/kidney failure 
Renal failure requiring dialysis 
Renal failure not requiring dialysis 
Kidney nephropathy 
Immunoglobulin A (IgA) nephropathy 
Prostate disorders Prostate problem (not cancer) 
Enlarged prostate 
Benign prostatic hypertrophy 
Glaucoma Glaucoma 
Epilepsy Epilepsy 
Dementia Dementia/Alzheimer/cognitive impairment 
Psoriasis or eczema Eczema/dermatitis 
Psoriasis 
Migraine Migraine 
Chronic sinusitis Chronic sinusitis 
Anorexia or bulimia Anorexia, bulimia/other eating disorder 
Parkinson’s disease Parkinson’s disease 
Multiple sclerosis Multiple sclerosis 
Chronic fatigue syndrome Chronic fatigue syndrome 
Endometriosis Endometriosis 
Meniere disease Meniere disease 
Pernicious anaemia Pernicious anaemia 
Polycystic ovaries Polycystic ovaries 
*Self-report lifetime diagnosis by doctor recorded by nurse-led interview (UK Biobank data field 
20002), except cancer diagnosis which was reported by touch-screen questionnaire. The list of 
disease groupings was based on Barnett et al (2012) 
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Selection of anticholinergic scales 532 
 533 
The identification of anticholinergic scales included in this analysis was based on searches for a 534 
systematic literature review (registered on PROSPERO: 535 
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017076510). The review itself 536 
is ongoing, and findings will be published elsewhere. Search strategy and identification of scales is 537 
summarized here briefly to explain the choice of scales included in this review.  538 
 539 
Medline and Embase were searched up until September 2017 using the following terms: 540 
 541 
anticholinergic*.mp or anti-cholinergic*.mp or cholinergic antagonist*.mp or antimuscarinic*.mp or 542 
anti-muscarinic*.mp or muscarinic antagonist*.mp 543 
AND 544 
scale*.mp or score*.mp or rank*.mp or rating*.mp or grading*.mp or index.mp or classification.mp 545 
 546 
Titles and abstracts here screened by 2 reviewers to identify studies in which anticholinergic 547 
medication scales have been validated. 548 
 549 
From 6558 abstracts screened, 377 full texts were identified as potentially relevant and screened for 550 
inclusion. From these, 14 anticholinergic scales were identified.  551 
 552 
Of these 14 scales, 4 were excluded from this UK Biobank analysis: 553 
- Summers’ list (Summers 1978): This was not specifically an anticholinergic scale, and also was 554 
likely to exclude many more recent medications. 555 
- Ancelin 2006: This was not a scale constructed for this study, but rather the application of an 556 
existing scale to a new cohort of patients. Only those medication found in the cohort were listed 557 
in the paper, hence we could not re-create the full scale from this text. 558 
- Ellett 2014: This paper listed anticholinergic medication identified from a range of existing scales 559 
(all of which were included in our analysis). Medications scoring “1” were also excluded. This 560 
was therefore not a distinct anticholinergic scale, rather a collection of medicaitons from 561 
existing scales already included in our analysis.  562 
- MARANTE (Klamer 2017): This scale was based on daily dosage calculations. As UK Biobank did 563 
not collect data on medication dosage we were unable to include this scale.  564 
 565 
This left 10 anticholinergic scales which were included in our analysis: Anticholinergic Drug Scale 566 
(ADS),8 Clinician-rated Anticholinergic Scale (CrAS),5 Anticholinergic Risk Scale (ARS),4 Anticholinergic 567 
Cognitive Burden (ACoB),3 Anticholinergic Activity Scale (AAS),6 revised Anticholinergic Activity Scale 568 
 39 
(AAS-r),7 Anticholinergic Loading Scale (ALS),9 Modified Anticholinergic Risk Scale (m-ARS),12 569 
Anticholinergic Effect on Cognition (AEC),10 Anticholinergic Impregnation Scale (AIS).11 570 
 571 
 572 
 573 
 574 
 575 
 576 
 577 
  578 
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Anticholinergic medications and their classification according to each anticholinergic medication 579 
scale. 580 
 581 
Medication 
A
IS
 
A
EC
 
m
A
R
S 
A
C
o
B
 
A
A
S 
(C
h
ew
) 
A
LS
 
A
A
S 
(E
h
rt
)†
 
C
rA
S 
A
R
S 
A
D
S 
Alimemazine 1 3 
 
1 
      
Alprazolam 1 
  
1 
 
1 
 
1 
 
1 
Alverine 1 
  
1 
      
Amantadine 2 2 2 2 
    
2 1 
Amiodarone 
 
1 
        
Amitriptyline 3 3 3 3 3 3 3 3 3 3 
Amoxapine 3 
  
3 
      
Ampicillin 1 
        
1 
Aripiprazole 
 
1 
        
Atenolol 1 
  
1 
   
1 
  
Atropine 3 3 3 3 3 3 
 
3 3 3 
Azathioprine 1 
        
1 
Baclofen 2 
 
2 
    
2 2 
 
Belladonna 
   
2 
   
3 
  
Benazepril 
       
1 
  
Benztropine 
 
3 3 3 
  
3 
 
3 3 
Betaxolol 
       
1 
  
Biperiden 3 
         
Bisacodyl 
     
1 
    
Bromocriptine 1 1 
       
1 
Brompheniramin
e 3 
  
3 
     
3 
 41 
Bupropion 1 
  
1 
   
1 
  
Captopril 1 
  
1 
     
1 
Carbamazepine 2 1 
 
2 
   
1 
 
2 
Carbidopa ± 
levodopa 1 
 
1 
  
1 
 
1 1 
 
Carbinoxamine 
   
3 
     
3 
Carisoprodol 
        
3 
 
Cefamandole 
         
1 
Cefoxitin 1 
        
1 
Celecoxib 
     
1 
    
Cephalothin 
         
1 
Cetirizine 2 
 
2 
  
2 
 
2 2 
 
Chlordiazepoxide 1 
      
1 
 
1 
Chlorphenamine 3 2 3 3 
 
3 
 
3 3 3 
Chlorpromazine 3 3 3 3 2 
  
3 3 3 
Chlorthalidone 1 
  
1 
     
1 
Cimeditine 2 
 
2 1 
    
2 2 
Citalopram 1 1 
  
1 1 1 
   
Clemastine 
 
3 3 3 
     
3 
Clindamycin 1 
        
1 
Clomipramine 3 3 2 3 
     
3 
Clonazepam 1 
    
1 
   
1 
Clorazepate 1 
  
1 
     
1 
Clozapine 3 3 2 3 3 
 
3 
 
2 3 
Co-codamol 
   
2 
      
Codeine 1 
  
1 
 
1 
 
1 
 
1 
Colchicine 1 
  
1 
      
 42 
Cortisone 
         
1 
Cyamemazine 3 
         
Cyclobenzaprine 
   
2 
   
1 2 2 
Cycloserine 
         
1 
Cyclosporine 1 
        
1 
Cyproheptadine 3 3 3 2 
 
3 
  
3 2 
Darifenacin 
  
2 3 
     
3 
Desipramine 
 
2 2 3 
   
2 2 3 
Desloratadine 3 
         
Dexamethasone 1 
        
1 
Dexchlorphenira
mine 3 
    
3 
    
Dextromethorpha
n 
       
1 
  
Diazepam 1 1 
 
1 
 
1 1 1 
 
1 
Dicycloverine/dic
yclomine 
 
2 3 3 3 
   
3 3 
Digitoxin 
      
1 
  
1 
Digoxin 1 
  
1 
 
1 1 
  
1 
Diltiazem 1 
        
1 
Dimenhydrinate 3 2 
 
3 
     
3 
Diphenhydramine 3 2 
 
3 2 
  
3 3 3 
Dipyridamole 
   
1 
     
1 
Disopyramide 2 2 
 
1 
     
2 
Divalproex 
sodium 1 
        
1 
Domperidone 1 1 
   
1 
    
 43 
Dothiepin/dosule
pin 2 3 2 
  
2 
    
Doxepin 3 3 2 3 3 3 3 3 
 
3 
Doxylamine 2 
         
Duloxetine 1 
         
Emepronium 
      
3 
   
Entacapone 1 
 
1 
     
1 
 
Escitalopram 
    
1 1 
    
Estazolam 
         
1 
Famotidine 1 
        
1 
Fentanyl 1 1 
 
1 
     
1 
Fesoterodine 
  
2 
       
Fexofenadine 2 
    
2 
 
2 
  
Flavoxate 3 
 
2 3 
     
3 
Flunitrazepam 
      
1 
   
Fluoxetine 1 1 
  
1 1 1 1 
 
1 
Fluphenazine 3 1 3 
  
3 
  
3 1 
Flurazepam 
         
1 
Fluticasone-
salmeterol 
         
1 
Fluvoxamine 1 
  
1 
 
1 1 
  
1 
Furosemide 
   
1 
  
1 
  
1 
Gentamicin 1 
        
1 
Guaifenesin 
       
1 
  
Haloperidol 1 
 
1 1 
 
2 
  
1 
 
Homatropine 
       
3 
  
Hydralazine 
   
1 
     
1 
 44 
Hydrocodone/dih
ydrocodeinone 
       
2 
  
Hydrocortisone 1 
  
1 
     
1 
Hydroxyzine 3 1 3 3 
    
3 3 
Hyoscine/scopola
mine 3 3 
 
3 
   
3 
 
3 
Hyoscyamine/L-
hyoscyamine 
  
3 3 3 
   
3 3 
Iloperidone 
 
1 
        
Imipramine 3 3 3 3 
 
3 
 
3 3 3 
Ipratropium 3 
     
3 
   
Isosorbide 1 
  
1 
     
1 
Isosorbide 
dinitrate 
         
1 
Isosorbide 
mononitrate 
         
1 
Ketorolac 
       
1 
  
Ketotifen* 
         
1 
Lansoprazole 
      
1 
   
Levodopa 1 
         
Levomepromazin
e/methotrimepra
zine 2 2 2 2 
     
2 
Lithium 1 1 
  
1 1 
    
Lofepramine 
 
3 1 
       
Loperamide 2 
 
2 1 
 
1 
 
1 2 1 
Loratadine 2 
 
2 
  
1 
 
1 2 
 
Lorazepam 1 
        
1 
Loxapine 2 
  
2 
     
2 
 45 
Lumiracoxib 
     
1 
    
Maprotiline 3 
         
Meclozine/meclizi
ne 
   
3 
    
3 3 
Meperidine/pethi
dine 2 2 
 
2 
     
2 
Mequitazine 3 
         
Metformin 
     
1 
    
Methadone 2 
      
2 
  
Methocarbamol 1 
 
1 
    
1 1 
 
Methotrexate 
     
1 
    
Methylprednisolo
ne 1 
        
1 
Metoclopramide/
Reglan 1 
 
1 
  
1 
 
3 1 
 
Metoprolol 1 
  
1 
   
1 
  
Midazolam 1 
        
1 
Mirtazapine 1 1 1 
 
1 
   
1 
 
Molindone 
   
2 
     
2 
Morphine 1 
  
1 
   
1 
 
1 
Naratriptan 
     
1 
    
Nefazodone 
       
1 
  
Nifedipine 1 
  
1 
     
1 
Nizatidine 1 
        
1 
Nortriptyline 3 3 2 3 2 
 
2 3 2 3 
Olanzapine 2 2 2 3 2 
 
2 1 2 1 
Orphenadrine 
 
3 3 3 
  
3 
  
3 
Oxazepam 1 
    
1 
   
1 
 46 
Oxcarbazepine 2 
  
2 
     
2 
Oxybutynin 3 3 3 3 2 2 3 
 
3 3 
Oxycodone 1 
    
1 
 
1 
 
1 
Pancuronium 
         
1 
Paroxetine 2 2 1 3 2 2 2 2 1 1 
Perphenazine 3 1 3 3 
   
2 3 1 
Phenelzine 1 
        
1 
Phenobarbital 
      
1 1 
  
Pimozide 2 2 
 
2 
     
2 
Piperacillin 1 
        
1 
Pipotiazine 1 
         
Pramipexole 1 
 
1 
     
1 
 
Prednisolone 1 1 
       
1 
Prednisone 1 
  
1 
     
1 
Prochlorperazine 2 2 2 
  
2 
 
2 2 1 
Procyclidine 
 
3 3 3 
     
3 
Promazine 
 
2 
 
3 
  
2 
   
Promethazine 3 3 3 3 
    
3 3 
Propantheline 
 
2 
 
3 
   
2 
 
3 
Propericiazine/pe
ricyazine 1 
 
2 
       
Propiverine 
  
2 
       
Propoxyphene 
      
1 2 
  
Protriptyline 
     
3 
   
3 
Pseudoephedrine 
± triprolidine 2 
 
2 
  
2 
  
2 
 
Pyrilamine/mepry
amine 
   
3 
     
3 
 47 
Quetiapine 2 2 1 3 1 
 
1 2 1 
 
Quinidine 1 1 
 
1 
      
Ranitidine 1 
 
1 1 1 1 1 2 1 2 
Reboxetine 
  
1 
       
Risperidone 1 
 
1 1 
 
1 
 
1 1 
 
Robitussin 
       
1 
  
Selegiline 1 
 
1 
     
1 
 
Sertindole 
 
1 
        
Sertraline 1 1 
     
1 
 
1 
Solifenacin 3 1 2 
       
Sumatriptan 
     
1 
    
Temazepam 1 1 
  
1 1 
   
1 
Theophylline 1 
  
1 
 
2 1 
  
1 
Thioridazine 
  
3 3 3 
 
3 3 3 3 
Thiothixine 
        
3 1 
Tiotropium 
  
2 
       
Tizanidine 3 
 
3 
     
3 
 
Tolterodine 3 2 2 3 3 3 
 
3 2 3 
Tramadol 1 
    
2 
 
2 
 
1 
Trandolapril 
       
1 
  
Trazodone 1 
 
1 1 
   
1 1 
 
Triamcinolone 1 
        
1 
Triamterene 1 
  
1 
     
1 
Triazolam 
       
1 
 
1 
Trifluoperazine 
 
2 3 3 
    
3 1 
Trihexyphenidyl/
Benzhexol 3 3 
 
3 
  
3 3 
 
3 
 48 
 582 
 583 
 584 
 585 
*Ophthalmic preparation. 586 
†Original 4-point scale modified by combining scores ‘1’ or ‘2’ to score as ‘1’, scoring ‘3’ as ‘2’, and 587 
‘4’ as ‘3’ to fit the 3-point scale system of other scales. 588 
 589 
 590 
 591 
 592 
 593 
Trimipramine 3 3 2 3 
  
3 
  
3 
Triprolidine 2 
         
Tropatepine 3 
         
Trospium 3 
 
2 
       
Valproic acid 1 
        
1 
Vancomycin 1 
        
1 
Venlafaxine 
     
1 
 
1 
  
Warfarin 1 
  
1 
     
1 
Ziprasidone 
        
1 
 
Zolmitriptan 
     
1 
    
